Drawing based on the description in the official product monograph. No photo yet.
“6 . DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. . Table 2 -. Dosage Forms, Strengths,. Composition and Packaging Route of Administration oral Dosage Form / Strength/Composition Tablet 250 mg Non-medicinal Ingredients Colloidal silica (anhydrous), Croscarmellose sodium, Hypromellose, Hypromellose acetate succinate, Indigo carmine aluminum lake, Lactose monohydrate, Magnesium stearate, Micro”
IVO 250 pill
Pill with imprint IVO 250 is blue, oval, 18 mm and has been identified as Ivosidenib 250 mg. It is used for acute myeloid leukemia. It is supplied by Servier Canada Inc.
Sold in Canada
Ivosidenib 250 mg
- Brand
- Tibsovo
- Imprint
- IVO 250
- Strength
- 250 mg
- Used for
- Acute myeloid leukemia
- Color
- Blue
- Shape
- Oval
- Size
- 18 mm
- Form
- Tablet (immediate-release)
- Manufacturer
- Servier Canada Inc
- Drug class
- Isocitrate dehydrogenase 1 inhibitor
- Sold in
- Canada
- DIN
- 02549980
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Ivosidenib used for?
Ivosidenib is used for acute myeloid leukemia.
- Medicine type
- Isocitrate dehydrogenase 1 inhibitor
Official uses from the US prescribing label
Newly Diagnosed Acute Myeloid Leukemia
TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Relapsed or Refractory Acute Myeloid Leukemia
TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Relapsed or Refractory Myelodysplastic Syndromes
TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Locally Advanced or Metastatic Cholangiocarcinoma
TIBSOVO is indicated for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
From the FDA-approved label on DailyMed (published Dec 22, 2025).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows IVO 250. The parts can be split between the two sides, so turn the pill over and check both.
- It is blue, oval, 18 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Tibsovo by Servier Canada Inc.
In Canada: prescription only.
Ingredients
Active: Ivosidenib
Other pills with imprint IVO 250
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
LAC 200
Lacosamide 200 mg
Blue, oval, 17 mm
Used for focal seizures and tonic-clonic seizures
Schedule V
-
OPC 50
Opicapone 50 mg
Blue, oval, 19 mm
Used for Parkinson's disease
-
OPC 25
Opicapone 25 mg
Blue, oval, 19 mm
Used for Parkinson's disease
-
IF826
Ibuprofen and Famotidine 800 mg / 26.6 mg
Blue, oval, 19 mm
Used for arthritis
-
AC11
Etodolac 500 mg
Blue, oval, 19 mm
Used for pain and rheumatoid arthritis
- RP 300 Maraviroc 300 mg Blue, oval, 19 mm Used for HIV